UY33652A - STABILIZED FORMULATIONS CONTAINING ANTI-RECEIVER ANTIBODIES OF INTERLEUCINE-4 (IL-AR) - Google Patents
STABILIZED FORMULATIONS CONTAINING ANTI-RECEIVER ANTIBODIES OF INTERLEUCINE-4 (IL-AR)Info
- Publication number
- UY33652A UY33652A UY33652A UY33652A UY33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A
- Authority
- UY
- Uruguay
- Prior art keywords
- interleucine
- antibodies
- receiver
- formulations containing
- containing anti
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 abstract 2
- 102000054663 human IL4R Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo humano que se une específicamente al receptor de interleucina-4 humano (hIL-4R). Las formulaciones pueden contener, además de un anticuerpo anti-hlL-4R, al menos un aminoácido, al menos un carbohidrato, o al menos un tensoactivo no iónico. Las formulaciones farmacéuticas de la presente invención exhiben un grado sustancial de estabilidad del anticuerpo d espués del almacenamiento durante varios meses.The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to the human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hlL-4R antibody, at least one amino acid, at least one carbohydrate, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39028310P | 2010-10-06 | 2010-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33652A true UY33652A (en) | 2012-04-30 |
Family
ID=45995014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY33652A UY33652A (en) | 2010-10-06 | 2011-10-06 | STABILIZED FORMULATIONS CONTAINING ANTI-RECEIVER ANTIBODIES OF INTERLEUCINE-4 (IL-AR) |
Country Status (14)
| Country | Link |
|---|---|
| AR (1) | AR083338A1 (en) |
| DK (2) | DK2624865T3 (en) |
| ES (2) | ES2820246T3 (en) |
| HK (1) | HK1258305A1 (en) |
| HR (1) | HRP20181822T1 (en) |
| HU (1) | HUE052089T2 (en) |
| LT (1) | LT2624865T (en) |
| PT (1) | PT3354280T (en) |
| RS (1) | RS57850B1 (en) |
| SI (1) | SI2624865T1 (en) |
| SM (1) | SMT201800488T1 (en) |
| TW (7) | TWI498121B (en) |
| UA (1) | UA111731C2 (en) |
| UY (1) | UY33652A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015003590A8 (en) | 2012-08-21 | 2017-10-31 | Sanofi Sa | METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF AN IL-4R ANTAGONIST |
| HUE046410T2 (en) * | 2013-06-21 | 2020-03-30 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| AU2014284235B2 (en) * | 2013-06-21 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| WO2016077675A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| PL3703818T3 (en) | 2017-10-30 | 2024-03-25 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| ES2332082B1 (en) * | 2008-07-24 | 2010-10-26 | Consejo Superior De Investigaciones Cientificas (Csic) 45% | PATTERN ALIGNMENT SYSTEM IN A SUBSTRATE BY LITOGRAPHY BY ESTENCIL. |
| KR101593726B1 (en) * | 2008-09-10 | 2016-02-18 | 니혼 엑스란 고교 (주) | Crosslinked acrylate-based fibers and the production thereof |
| CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
-
2011
- 2011-05-10 UA UAA201305598A patent/UA111731C2/en unknown
- 2011-10-03 AR ARP110103663 patent/AR083338A1/en not_active Application Discontinuation
- 2011-10-05 TW TW100135992A patent/TWI498121B/en active
- 2011-10-05 ES ES18161288T patent/ES2820246T3/en active Active
- 2011-10-05 TW TW109131629A patent/TWI782325B/en active
- 2011-10-05 TW TW105134483A patent/TWI679988B/en active
- 2011-10-05 TW TW109107375A patent/TWI718890B/en active
- 2011-10-05 RS RS20181308A patent/RS57850B1/en unknown
- 2011-10-05 TW TW111138434A patent/TWI856388B/en active
- 2011-10-05 DK DK11770625.9T patent/DK2624865T3/en active
- 2011-10-05 SM SM20180488T patent/SMT201800488T1/en unknown
- 2011-10-05 TW TW104123984A patent/TWI568445B/en active
- 2011-10-05 LT LTEP11770625.9T patent/LT2624865T/en unknown
- 2011-10-05 TW TW108111631A patent/TWI690329B/en active
- 2011-10-05 HU HUE18161288A patent/HUE052089T2/en unknown
- 2011-10-05 PT PT181612888T patent/PT3354280T/en unknown
- 2011-10-05 DK DK18161288.8T patent/DK3354280T3/en active
- 2011-10-05 ES ES11770625.9T patent/ES2687813T3/en active Active
- 2011-10-05 SI SI201131568T patent/SI2624865T1/en unknown
- 2011-10-06 UY UY33652A patent/UY33652A/en unknown
-
2018
- 2018-10-31 HR HRP20181822TT patent/HRP20181822T1/en unknown
-
2019
- 2019-01-15 HK HK19100671.5A patent/HK1258305A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1258305A1 (en) | 2019-11-08 |
| TW201716086A (en) | 2017-05-16 |
| TW202320851A (en) | 2023-06-01 |
| PT3354280T (en) | 2020-09-01 |
| HUE052089T2 (en) | 2021-04-28 |
| DK3354280T3 (en) | 2020-09-28 |
| SMT201800488T1 (en) | 2018-11-09 |
| TW202026011A (en) | 2020-07-16 |
| TWI690329B (en) | 2020-04-11 |
| TW202102262A (en) | 2021-01-16 |
| TWI856388B (en) | 2024-09-21 |
| TW201221141A (en) | 2012-06-01 |
| RS57850B1 (en) | 2018-12-31 |
| ES2687813T3 (en) | 2018-10-29 |
| HRP20181822T1 (en) | 2018-12-28 |
| ES2820246T3 (en) | 2021-04-20 |
| TWI718890B (en) | 2021-02-11 |
| TW201542229A (en) | 2015-11-16 |
| TWI498121B (en) | 2015-09-01 |
| TWI782325B (en) | 2022-11-01 |
| SI2624865T1 (en) | 2018-10-30 |
| TWI679988B (en) | 2019-12-21 |
| DK2624865T3 (en) | 2018-10-22 |
| TW201924718A (en) | 2019-07-01 |
| AR083338A1 (en) | 2013-02-21 |
| LT2624865T (en) | 2018-10-25 |
| UA111731C2 (en) | 2016-06-10 |
| TWI568445B (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012092A (en) | STABILIZED FORMULATIONS CONTAINING ANTI-BODY ANTIBODIES OF INTERLEUQUINA-6 (IL-6R) | |
| CY1121233T1 (en) | STABILIZED PREPARATIONS CONTAINING ANTIBODIES AT THE INTERLEUKIN-4 RECEPTOR (IL-4R) | |
| UY33515A (en) | STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES | |
| CY1122181T1 (en) | PHARMACEUTICAL FORM OF ANTIBODY | |
| AR122746A2 (en) | A STABLE LIQUID ANTIBODY PHARMACEUTICAL FORMULATION | |
| CO2019011021A2 (en) | Stable antibody formulation | |
| MX357393B (en) | Stabilized formulations containing anti-ang2 antibodies. | |
| MY157772A (en) | Antibody formulation | |
| MX375672B (en) | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES. | |
| CR10555A (en) | VACCINES FOR MALARIA | |
| MX2009005414A (en) | Liquid anti-rabies antibody formulations. | |
| UY33652A (en) | STABILIZED FORMULATIONS CONTAINING ANTI-RECEIVER ANTIBODIES OF INTERLEUCINE-4 (IL-AR) | |
| CO2021011648A2 (en) | Stabilized formulations containing anti-il-33 antibodies | |
| TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
| EA202090016A2 (en) | STABILIZED COMPOSITIONS CONTAINING ANTIBODIES TO INTERLEUKIN-4 (IL-4R) RECEPTOR | |
| TH175929A (en) | Antibody Formulation |